Q-omics provides the consensus-scored GUSBP12 profile across patient tissues and cancer cell-line models. GUSBP12 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GUSBP12 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, GUSBP12 RNA expression shows 12,643 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LIHC, and TGCT as cancer lineages where GUSBP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP12 survival associations across molecular data types. GUSBP12 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP12 RNA expression–survival associations across cancer types. High GUSBP12 expression shows unfavorable associations in KICH, COAD, PCPG and KIRP, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for GUSBP12 RNA expression.
This table summarizes GUSBP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP12 shows higher tumor expression in LIHC. The LIHC box plot shows higher GUSBP12 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .043).
This table shows molecular features associated with GUSBP12 in patient tissues and cancer cell lines. In patient samples, GUSBP12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
